TW202323296A - 組合療法 - Google Patents

組合療法 Download PDF

Info

Publication number
TW202323296A
TW202323296A TW111132340A TW111132340A TW202323296A TW 202323296 A TW202323296 A TW 202323296A TW 111132340 A TW111132340 A TW 111132340A TW 111132340 A TW111132340 A TW 111132340A TW 202323296 A TW202323296 A TW 202323296A
Authority
TW
Taiwan
Prior art keywords
dose
glp
agonist
actrii receptor
receptor antibody
Prior art date
Application number
TW111132340A
Other languages
English (en)
Chinese (zh)
Inventor
勞埃德 伯爾 克利克斯坦
馬蒂亞斯 馬哈切克
Original Assignee
美商維紗妮絲生物公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維紗妮絲生物公司 filed Critical 美商維紗妮絲生物公司
Publication of TW202323296A publication Critical patent/TW202323296A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111132340A 2021-08-27 2022-08-26 組合療法 TW202323296A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163238068P 2021-08-27 2021-08-27
US63/238,068 2021-08-27
US202263301012P 2022-01-19 2022-01-19
US63/301,012 2022-01-19
US202263333351P 2022-04-21 2022-04-21
US63/333,351 2022-04-21

Publications (1)

Publication Number Publication Date
TW202323296A true TW202323296A (zh) 2023-06-16

Family

ID=83897998

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132340A TW202323296A (zh) 2021-08-27 2022-08-26 組合療法

Country Status (11)

Country Link
US (1) US20240325530A1 (cg-RX-API-DMAC7.html)
EP (1) EP4392137A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532619A (cg-RX-API-DMAC7.html)
KR (1) KR20240099142A (cg-RX-API-DMAC7.html)
CN (1) CN118488853A (cg-RX-API-DMAC7.html)
AU (1) AU2022332306A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229355A1 (cg-RX-API-DMAC7.html)
IL (1) IL310919A (cg-RX-API-DMAC7.html)
MX (1) MX2024002467A (cg-RX-API-DMAC7.html)
TW (1) TW202323296A (cg-RX-API-DMAC7.html)
WO (1) WO2023028606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
EP4466288A4 (en) * 2022-01-19 2026-02-25 Versanis Bio Inc ACTRII ANTIBODY-BASED TREATMENTS
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4577301A1 (en) 2022-08-26 2025-07-02 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
IL326224A (en) 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
IL330385A (en) * 2023-12-29 2026-08-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Antibody-polypeptide conjugate and its pharmaceutical use
WO2025147483A1 (en) * 2024-01-02 2025-07-10 Keros Therapeutics, Inc. Methods of using activin receptor type ii chimeras
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
WO2025247309A1 (zh) * 2024-05-31 2025-12-04 上海齐鲁制药研究中心有限公司 融合蛋白分子及其应用
WO2026128614A1 (en) * 2024-12-10 2026-06-18 Supercede Therapeutics, Inc. Activin receptor type ii inhibitors for preventing or treating obesity and related disorders
EP4785960A1 (en) 2025-01-31 2026-08-05 SixPeaks Bio AG Glp-1 antibody conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018129395A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation

Also Published As

Publication number Publication date
US20240325530A1 (en) 2024-10-03
MX2024002467A (es) 2024-05-20
EP4392137A1 (en) 2024-07-03
WO2023028606A1 (en) 2023-03-02
AU2022332306A1 (en) 2024-02-29
CA3229355A1 (en) 2023-03-02
IL310919A (en) 2024-04-01
CN118488853A (zh) 2024-08-13
KR20240099142A (ko) 2024-06-28
JP2024532619A (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
US20240325530A1 (en) Combination therapies
TWI477273B (zh) 低頻率格拉替雷(glatiramer)醋酸鹽之治療
EP4358995B1 (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
JP2024532619A5 (cg-RX-API-DMAC7.html)
JP7663559B2 (ja) Actrii受容体拮抗薬を含む肝疾患または肝臓障害の治療
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
CN118055767A (zh) 新颖的组合施用
US20260070992A1 (en) Actrii antibody fixed unit dose treatments
KR20200076705A (ko) 둘라글루티드를 함유하는 조성물 및 사용 방법
TW202339798A (zh) Actrii抗體之治療
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
AU2021293980B2 (en) Treatment of food allergy using anti-IgE antibodies
TW201625289A (zh) 使用glp-1及抗il-21治療糖尿病
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
WO2025183966A1 (en) Actrii antibodies with extended half life
CN121969358A (zh) 选择性雄激素受体调节剂(sarm)化合物在长期体重管理中的用途
HK40103690A (en) Novel combined administration
TW202612733A (zh) 抗IL-11Rα抗體在治療甲狀腺眼病中之給藥